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Abstract
Background: Substituted flavanoids interfere with uncoating of Enteroviruses including Sabin-2 polio vaccine strains.
However flavanoid resistant and dependent, type-2 polio vaccine strains (minimally-diverged), emerged during in vitro
infections. Between 1998–2009, highly-diverged (8 to .15%) type-2, aVDPV2s, from two unrelated persistent infections
were periodically isolated from Israeli sewage.
Aim: To determine whether highly evolved aVDPV2s derived from persistent infections retained sensitivity to isoflavenes.
Methods: Sabin-2 and ten aVDPV2 isolates from two independent Israeli sources were titered on HEp2C cells in the presence
and absence of 3(2H)- Isoflavene and 6-chloro-3(2H)-Isoflavene. Neurovirulence of nine aVDPV2s was measured in PVR-Tg-21
transgenic mice. Differences were related to unique amino acid substitutions within capsid proteins.
Principal Findings: The presence of either flavanoid inhibited viral titers of Sabin-2 and nine of ten aVDPV2s by one to two
log10. The tenth aVDPV2, which had unique amino acid substitution distant from the isoflavene-binding pocket but
clustered at the three- and five-fold axies of symmetry between capsomeres, was unaffected by both flavanoids. Genotypic
neurovirulence attenuation sites in the 59UTR and VP1 reverted in all aVDPV2s and all reacquired a full neurovirulent
phenotype except one with amino acid substitutions flanking the VP1 site.
Conclusion: Both isoflavenes worked equally well against Sabin 2 and most of the highly-diverged, Israeli, aVDPV2s isolates.
Thus, functionality of the hydrophobic pocket may be unaffected by selective pressures exerted during persistent poliovirus
infections. Amino acid substitutions at sites remote from the drug-binding pocket and adjacent to a neurovirulence
attenuation site may influence flavanoid antiviral activity, and neurovirulence, respectively.
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Introduction
Poliovirus is a member of the Picornaviridae. Like other members
of the Picornaviridae, poliovirus RNA is encapsidated in an
icosahedral structure with axes of three-fold and five-fold
symmetry formed from 60 capsomeres containing one copy each
of viral capsid proteins VP1, VP2, VP3 and VP4 [1]. The binding
site for the human poliovirus receptor is located in a canyon at the
five-fold axis of symmetry. The VP1 of picornaviruses contain a
hydrophobic pocket that is accessed through this canyon. This
pocket is normally occupied by pocket factors, sphingosine-like
molecules including palmitic and myristic acids and hydrophobic
compounds, that stabilize the capsid and whose removal is a
necessary prerequisite for uncoating [2].
Flavanoids and flavonoids were shown to have antiviral activity
in vitro against several picornaviruses including type 2 polioviruses
[3,4,5,6,7,8]. These compounds act primarily by occupying the
hydrophobic pocket, thus interfering with virus uncoating. They
did not directly affect viral adsorption or RNA synthesis [4].
Mutations that interfered with the antiviral activity of these
compounds appeared during in vitro replication of type 2 polio
vaccine strains in the presence of these compound [4]. Some
mutations acted directly by affecting binding while others exerted
their effect indirectly by altering viral capsid stability.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e18360Since the adoption of the Global Poliomyelitis Eradication
Initiative of the WHO in 1988 [World Health Assembly resolution
WHA41.28], the use of live attenuated trivalent Sabin polio
vaccine, inactivated Salk polio vaccine, or a combination of both
has drastically reduced the global morbidity and mortality caused
by the three types of poliovirus [For latest update see http://www.
polioeradication.org/]. Three problems have contributed towards
the delay in achieving global eradication; failure to vaccinate all of
the children in a region as in Nigeria [9,10,11,12], oral vaccine
failure probably related to interference by other enteric microor-
ganisms coupled with the presence of high amounts of wild
poliovirus in the environment, as in the Bihar and Uttar Pradesh
States in India [11,13,14], and relatively rare outbreaks of
poliomyelitis caused by vaccine-derived polioviruses (VDPVs) that
reverted to wild phenotype [15,16]. A VDPV is a poliovirus that
has evolved from one of the three vaccine serotypes after
prolonged replication, probably sustained by low immunity
coverage or immunodeficiency and whose VP1 capsid protein
sequence has diverged from its respective oral vaccine serotype by
1 to 15% [17]. When divergence is .15%, but an isolate can be
phylogenetically linked to a previously identified VDPV, it is still
designated as a VDPV. VDPVs evolve during person-to-person
transmission of live-attenuated vaccine (cVDPVs) or through
persistent infections of immunodeficient individuals (iVDPVs)
[16]. Ambiguous VDPVs, such as environmental isolates, for
which the evolutionary pathway cannot be assigned, are called
aVDPVs.
Israel has been poliomyelitis free since 1989. A countrywide
sewage surveillance program was introduced in 1989 to search for
the presence or circulation of wild poliovirus or VDPVs before the
occurrence of cases of poliomyelitis [18]. In 1998 a polio virus
isolate that had diverged from Sabin 2 by 8% was identified in a
sewage sample from a collection site serving a population of 1.6
million in central Israel [19]. Iterative introduction of new
surveillance sites at major branch points upstream of sites yielding
positive samples was used to increase the chance of isolating
aVDPVs and to localize the geographical region of the excreter or
excreters. Between 1998 and 2009, a total of 43 aVDPVs that had
diverged from Sabin 2 vaccine by 8 to .15% were recovered from
33 sewage samples [20]. Based on time clocks for the accumulation
of synonymous single nucleotide substitutions, this would corre-
spond to a chain of continuous replication of at least 8 to 15 years
in one or more human host [21]. Sequence analyses strongly
suggested that all of the Israeli aVDPV2 isolates arose during
persistent infections of immune deficient individuals, and that
there were two separate epidemiological sources of persistent
infections in central Israel [22]. This conclusion was strengthened
when surveillance sites were introduced at upstream locations and
sewage samples from a trunk line serving ,350,000 individuals
exclusively yielded isolates from one of the two phylogenetically
related groups, while another trunk line serving 50,000 individuals
exclusively yielded isolates from the other phylogenetically related
group. Some of the aVDPV2 isolates from both groups were tested
and shown to be highly neurovirulent in a transgenic mouse model
system and amino acid substitutions in neutralizing antigenic
epitopes resulted in three-fold lower geometric mean neutralizing
antibody titers obtained against vaccine strains in sera from
cohorts of Israeli subjects aged between 15 months and 50 years
[22].
One potential source for reemergence of poliomyelitis after
eradication is from unidentified persistent infections. When
persistently infected individuals were identified (approximately
40 throughout the world to date) [15], efforts to cure the persistent
infections were in most cases not successful, as exemplified by
attempts to treat an immune-deficient individual in the United
Kingdom [23]. However, a combination of gammaglobulin
replacement therapy and pleconaril appeared effective for another
persistently infected individual [24]. There is currently no
universal, safe, orally administered antiviral that is effective against
poliovirus. Thus there remains an urgent need to develop effective
antivirals for curing persistent as well as transient poliovirus
infections as a complimentary or alternative approach to oral polio
vaccine for persistently infected individuals during the final stages
of eradication and for post-eradication re-emergence [25,26,27].
The present study was undertaken to determine whether highly-
diverged, Sabin 2 derived aVDPVs of different lineages that
evolved in vivo from two different as yet unidentified epidemiolog-
ical sources remained sensitive to isoflavenes in vitro as a first step in
evaluating the potential of these compounds to reduce viral loads
in vivo and or eliminate one or more lineage of VDPV that may co-
exist [22,28] in persistently infected immune deficient individuals.
Materials and Methods
Ethics Statement
This study did not require ERB approval. The viruses used in
these studies were anonymous aVDPVs isolated from environ-
mental samples. All animal model studies reported here were
approved by and conducted in accordance with the guidelines of
the Office of Laboratory Animal Care at the Pasteur Institute and
complied with French laws and regulations. Our study was
registered under the number 08188.
Compounds
3(2H)-Isoflavene (C2) and 6-chloro-3(2H)-Isoflavene (C10) were
synthesized as described [29][25]. Stock solutions were prepared
at a concentration of 1 mg per ml in ethanol and used at a final
concentration of 20 mM. An equivalent volume of ethanol was
added to control cultures.
Cell lines and viruses
HEp2C cells (ATCC CCL136) were grown at 37uC in Eagles
MEM supplemented with 10% fetal bovine serum (FBS), and
penicillin, 160 U/ml; streptomycin, 0.32 g/ml; and mycostatin,
20 U/ml (cell medium).
Sabin 2 strains of polio vaccine were obtained from Radu
Crainic, the Pasteur Institute, Paris, France and from NIBSC,
Hertfordshire, England. Ten highly diverged aVDPV2s represent-
ing three lineages each from epidemiological groups 1 and 2 [22]
were isolated as described from sewage samples collected from
central Israel between 1998 and 2007 [22,30][21,26]. Isolation of
the aVDPVs included selection for growth at 40uC within 5 days.
However, all isolates behaved like Sabin 2 at 37uC. High titered
viral stocks were prepared by infection of HEp2C cells at 37uand all
subsequent experiments were performed at this temperature. Partial
genomic sequences of the aVDPV2 isolates reported here have been
deposited in the EMBL/GenBank/DDJB database under the
following access numbers: PV2_4568-1_ISR98 (SD-98-01; AM
040035), PV2_5021-1_ISR99 (SD-99-01; AM040036), PV2_6056-
3_ISR04 (SD-04-01; AM056049), PV2_6316-1_ISR05 (SD-05-01;
AM056050), PV2_6526-1_ISR06 (SD-06-01; AM292219), PV2_
6669-1_ISR06 (SD-06-05; HQ703551), PV2_6670-1_ISR06 (SD-
06-06; HQ703552), PV2_6680-1_ISR06 (SD-06-09; HQ703553),
PV2_6701-1_ISR06 (SD-06-10; HQ703554), and PV2_6818-1_
ISR07 (SD-07-03; HQ703555). For convenience all VDPV isolate
names have been shortened to ‘‘SD’’ for Sabin-derived, a two digit
number indicating the year of isolation, and another two digits to
indicate the order of isolation with in a year when there was more
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2006, has been renamed SD-06-6).
Viral inhibition assay
Confluent monolayers of HEp2C cells were prepared in
individual wells of 96-well microtiter plates by plating 60–70,000
cells per well in 100 ml of cell medium and incubating the plates
overnight at 37uCi naC O 2 incubator. C2 or C10 compounds or
the equivalent volume of ethanol solvent was added to 25 ml of cell
medium so that final isoflavene concentration in the wells was
20 mM. After 6 hours, cell monolayers were infected with 25 mlo f
a ten-fold serial dilution of virus stocks in cell medium with 2%
FBS. Four replicate wells were used for each dilution. At the end of
72 hours of incubation at 37uC, cells were fixed and stained with
4% formaldehyde and crystal violet. The mean difference in
TCID50 was determined for each virus grown in the presence or
absence of isoflavenes from three independent experiments using
the Karber formula.
Neurovirulence test
Phenotypic neurovirulence was determined for nine of the ten
aVDPV2 isolates selected for this study using PVR-Tg21transgenic
mice [22,24][21,23] (provided by A. Nomoto and T. Nomura).
Eight-week old PVR-Tg21 transgenic mice were inoculated
intranasally (i.n.; 4 males; 3 females) or intraperitoneally (i.p.; 4
males; 3 females) with 10
6 and 10
7 TCID50 infectious doses of
each aVDPV isolate, respectively, and monitored daily for paresis,
paralysis, or death over a 21-day interval. All inoculation
experiments included fully attenuated and neurovirulent controls
in order to ensure that the inoculation process by itself was never
the cause of disease and that a highly neurovirulent inoculum lead
to disease or death in 100% of infected animals. The titers of the
virus stocks were confirmed before and after challenge.
Genetic analysis of capsid proteins and 59UTR
A portion of the 59UTR and the entire P1 genomic region
encoding all four capsid proteins was sequenced for all of the
aVDPV2s used in this study using primers and RT-PCR as
described in Shulman et. al [22]. Sequences were translated in silico
and compared to that of Sabin 2 (AY184220) using the
Sequencher program (Gene Codes Corp, Anne Arbor, Mi.).
Genotypic reversion to neurovirulence was evaluated by deter-
mining the nucleotide at position 481 in the 59UTR and the amino
acid at position 143 in VP1. Nearest-neighbor phylogenetic
analysis was performed using Clustal X [31] after bootstrapping
data 1000 times and the resulting phylogenetic tree visualized
using the njplot program [32]. Computer-assisted modeling of the
location of substituted amino acids was performed using the Mac
PyMol program (DeLano Scientfic. Palo Alto, Ca) to identify
equivalent positions on the three-dimensional structural [33] of
PV2 Lansing strain (PDB access number 1EAH).
Statistical analysis
A standard analysis of variance (SPSS, v18) was used to
determine the significance of differences in response to C2 and
C10 between all pairwise combinations among Sabin strains and
aVDPV2s. Both a Mixed Model for Repeated Measures (SAS v9.1)
and Tukeys method for multiple comparisons of repeated measures
of variants (SPSS, v18) were used to determine whether C10
treatment reduced viral titers to a greater extent than C2 for all
aVDPV2s. Pairwise statistical comparisons between virus-associated
disease development were made according to the Kaplan-Meier
method and tested for significance by using the log-rank test.
Results
Genomic characterization of reversion to neurovirulence
of aVDPV2 isolates used in this study
Ten highly diverged aVDPV2 isolates representing different
lineages of type 2 poliovirus from two epidemiologically unrelated
sources in Israel [20,22] were selected for analysis. A portion of the
59UTR and the complete P1 genomic region coding for VP1,
VP2, VP3 and VP4 capsid proteins were sequenced for all isolates.
All ten of the aVDPV2s had reverted to neurovirulent genotypes
[34], i.e., all had a reverted at nucleotide position 481 in the
59UTR (A to G) and at amino acid residue 143 of VP1 (isoleucine
encoded by ATT to threonine encoding by ACT). The
phylogenetic relationship between the VP1 genes of all of the
aVDPV2 isolates and Sabin 2 is shown in Fig. 1.
Phenotypic characterization of reversion to
neurovirulence of the aVDPV2 isolates
Nine of he highly diverged aVDPV isolates were used to
challenge PVR-Tg21 mice as described in Methods. The
percentage of healthy mice, i.e. those that had not developed
paresis or paralysis or had died was determined daily after i.p. or
i.n. inoculation (Fig. 2). Consistent with the genotypic reversion to
neurovirulence, less than 25% of the mice in groups innoculated
i.p. with eight of the aVDPV2 isolates and less than 28% of those
inoculated i.n. with seven of the eight aVDPV2s remained healthy
after five or eight days, respectively. Unexpectedly, more than
50% of the mice inoculated with isolate SD-07-03 by either route,
or SD-06-10 by the i.n. route, remained healthy at the end of the
observation periods (58% at 7 days post-i.p., 75% at 21 days post-
i.n., and 50% days post-i.n., respectively). Isolate SD-07-03 was
significantly less neurovirulent than the eight other isolates
following the i.n. and i.p. routes according to the log -rank test
(p#0.05 for 14 of 16 pairwise comparisons). Isolate SD-06-01
appears less neurovirulent in many cases (i.p. route: among 8
isolates p,0.05 in 4 cases and p,0.1 in 3 other cases).
Figure 1. Phylogenetic relationships among type 2 aVDPVs
isolated from sewage in Israel between 1998 and 2007. A
nearest-neighbor phylogenetic tree was prepared from the VP1
sequences (903 nt) of type 2 aVDPVs isolated from each of the different
lineages that were associated with two different epidemiological
sources [22] in central Israel using Clustal X and nj plot after
bootstrapping sequence data 1000 times. Branches with bootstrap
values less than 900 have been collapsed. The arrow indicates the
isolate that did not respond to either the C2 or C10 compounds. The
numbers in brackets indicate whether the isolate belongs to group 1 or
2 and the letter or letter and number that follows indicates the lineage
or sub lineage within each group.
doi:10.1371/journal.pone.0018360.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e18360Figure 2. Neurovirulence of the aVDPV2 isolates used in this study. Neurovirulence was determined for each aVDPV2 isolate in PVR TG-21
mice as described in Materials and Methods. Groups of four male and four female eight week-old PVR-TG21 mice were infected i.p. with 10
7 TCID50 of
each aVDPV2, while four male and three female mice were infected i.n. with 10
6 TCID50 of each aVDPV2. The graphs show daily percent of mice that
remained healthy during seven days or 21 days following i.p. and i.n. All mice in the groups injected by either route with equivalent titers of Sabin 2
remained healthy throughout the observation periods and all mice injected with fully neurovirulent controls became sick or died (not shown). Graphs
in red indicate those isolates that had not completely reverted to a neurovirulent phenotype despite the fact that all of the aVDPV2 isolates had
reverted to the neurovirulent genotype, ie had G substituted for A at nucleotide 481 of their 59UTR and threonine substituted for isoleucine at amino
acid residue143 of their VP1.
doi:10.1371/journal.pone.0018360.g002
Antiviral Isoflavenes and aVDPV2s
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e18360Inhibition of type 2 vaccine derived poliovirus (aVDPV)
replication in the presence of C2 and C10 compounds
The mean difference in viral titers for type 2 Sabin (2 sources)
and the 10 aVDPV2 polioviruses grown in the presence and
absence of C2 and C10 compounds was determined from three
independent titrations (Fig. 3). Standard analysis of variance
(SPSS) revealed that isolate SD-06-10 from epidemiological Group
2, was the only aVDPV2 isolate that had a significantly different
response than the Sabin 2 Pasteur strain in the presence of either
compound (p,0.01) and Sabin 2 NIBSC strain in the presence of
C10 (p,0.05). Furthermore SD-06-10 was also significantly
different (p,0.05) in its response to C10 from 5 of the other 9
aVDPV2s (the exceptions were SD-99-01, SD-06-09, SD-04-01
and SD-07-03; all from epidemiological Group 1). The replication
of aVDPV2 isolate SD-06-10 was unaffected when grown in the
presence of either compound. The change in SD-06-10 associated
with C10 was not statistically different from 0; the variation was
too large to exclude the possibility that the average increase (even
though each sample increased) was due to chance. For the Sabin 2
reference strains (from two different sources) and the other nine
aVDPV2s (isolated from two unrelated epidemiological events), the
presence of either compound reduced viral growth by one to two
logs. The mean differences in the presence of the drugs and their
standard errors are as follows: C2 21.07, SE=0.07; C10: 21.31,
SE=0.10. A repeated measures analysis of variance (Tukey’s
Method, SPSS), which takes into account the paired nature of the
C2/C10 differences, revealed that these mean differences were
statistically different (p=0.003). However, the C2 vs C10
comparison was not consistent across all isolates, as there was a
significant interaction (p=0.038). These findings are consistent
with results from analysis using the Mixed Model for Repeated
measures of the SAS (v9.1) program that also indicated that the
C10 compound was significantly more effective than the C2
compound in reducing viral titers for the nine aVDPVs that
responded to the antiviral affects of the two isoflavenes (t value
30.26; P,0.0001).
Three-dimensional mapping of unique amino acid
substitutions in capsid proteins of the isoflavene-
resistant aVDPV isolate, SD-06-10, and the
neurovirulence-attenuated aVDPV isolates, SD-07-03
C2 and C10 compounds exert their antiviral effect by
interacting with amino acids in the viral capsid pockets. Since
amino acid substitutions might have direct or indirect effects on
this interaction, the P1 sequences from the previous section were
translated in silico using the Sequencher program to determine
which amino acid substitutions in the capsid proteins were unique
in the SD-06-10 strain or shared with the other aVDPV2 isolates.
The unique and shared substitutions are listed in Table S1. Also
included in the table are the amino acid residues that define the
hydrophobic pocket as well as the substitutions conferring
isoflavene resistance or dependence to Sabin 2 as reported by
Salvati et al. [4].
The unique amino acid substitutions in isolate SD-06-10 were
mapped onto the three-dimensional x-ray crystallographic atomic
coordinates of type 2 poliovirus (PDB accession number1EAH)
(Fig. 4) using MacPyMol to determine their location with respect
to the isoflavene-binding pocket and to the capsomere junctions.
None of the unique substitutions appear to directly interact with
the binding pocket or with amino acid substitutions that were
previously identified by Salvati et al. [4] as those that indirectly
affected the response to isoflavenes. However, one unique
substitution at amino acid residue 6 of VP3, Ser6, was located in
the central junction of the five capsomeres at the five-fold axis of
symmetry (Fig. 4E.) and another unique substitution at residue 206
of VP3, Ser206, was located adjacent to the three fold axis of
symmetry (Fig. 4B) where they might influence capsid flexibility
and or stability Among all of the aVDPV isolates that were
sensitive to C2 and C10 and resistant strain SD-06-10, only isolate
SD-04-01, had two amino acid substitutions closer than five
residues from any of the amino acids listed in part a of Table S1
and highlighted in blue for Fig. 4 that represent the position of the
hydrophobic pocket. One was adjacent to VP1 residue 110 and
the other occurred two residues after VP1 residue 136.
A substitution of one or more of the nucleotides encoding amino
acid 143 of VP1 that results in replacement of Ile143 with Thr143 is
one of the two mutations considered necessary and sufficient to
reverse attenuation of neurovirulence for Sabin 2. The other is the
substitution of A with a G at nt position 481 of the 59UTR. Since
both substitutions were present in the genomes of all ten of the
aVDPV2s, all should have possessed a neurovirulent phenotype.
One isolate, SD-07-03, however, exhibited an almost fully
attenuated phenotype in transgenic mice infected by both the
i.p. and i.n. routes despite being derived from highly nurovirulent
ancestors and having both substitutions. Unique and shared amino
acid substitutions in the capsid proteins for isolate SD-07-03, listed
in Table S1, were mapped onto the 3-D capsid structure to infer
whether any of them might have contributed towards this
attenuated phenotype. Unique substitutions found in this strain
at residues 141, 143, and 145 of VP1 that flank Thr143 (Fig. 5E)
were more likely to counteract the effect of the reversion at residue
143 than substitutions in the 59 and 39 untranslated regions or in
the P2 and P3 coding regions (not sequenced) although the
contribution of substitutions in the non-capsid regions of the
Figure 3. The antiviral effects of C2 and C10 compounds on
aVDPV2 strains isolated from sewage in Israel between 1998
and 2007. The environmental isolates represent different lineages of
two unrelated epidemiological events. Replicate monolayers of HEp2C
cells in 96 well micro-titer plates were infected with 10-fold serial
dilutions of Sabin 2 from two different sources and with each aVDPV2
isolate. Infection was in the absence or presence of 20 mm of the C2 or
C10 compounds. The graph shows the mean of the log10 of the TCID50
from cell monolayers treated with C2 (light shading) or C10 (dark
shading) minus the log10 of the TCID50 from untreated cell monolayers.
The bars indicate the standard deviation from three separate
experiments.
doi:10.1371/journal.pone.0018360.g003
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located adjacent to the 5-fold axis of symmetry. None of SD-07-
03’s unique substitutions were located near the 3-fold axis of
symmetry.
An animated ‘‘Interactive 3D Complement’’ (I3DC) for the
structures in Fig. 4 and Fig. 5. appears in Proteopedia at http://
proteopedia.org/w/Journal:PLoS_ONE:1.
Discussion
Permanent global eradication of poliomyelitis requires the
elimination of all chains of transmission of poliovirus throughout
the world through immunization programs and improvement of
hygienic conditions and the subsequent containment and destruc-
tion of all stocks of poliovirus. Most national immunization
programs are based on the use of live oral Sabin vaccines (OPV) or
a combination of OPV and inactivated Salk vaccines (IPV). Of the
three impediments for successful eradication, failure to vaccinate
and vaccine failure result in continued person-to-person transmis-
sion of wild polio viruses and VDPVs. Intense efforts are underway
to increase vaccine coverage with conventional vaccines to
overcome the first problem, and to develop new vaccines or
vaccination strategies to deal with the second problem [11]. It is of
critical importance to rapidly reach and maintain effective high
Figure 4. Unique amino acid substitutions in the capsid proteins of an isoflavene resistant aVDPV2 isolate SD-06-10 mapped onto
the three-dimensional x-ray crystallographic atomic coordinates of type 2 poliovirus (PDB accession number1EAH). aVDPV2 isolate
SD-06-10 was resistant to the antiviral effects of both C2 and C10 compounds (Fig. 3) The in silico translated amino acid sequences of the capsid
proteins of all of the aVDPV2 isolates and Sabin 2 (AY184220) were compared and amino acid substitutions in capsid proteins that were unique to SD-
06-10 were determined (Table S1). The positions of these unique substitutions were mapped onto the coordinates of type 2 poliovirus (1EAH) using
MacPyMol and are represented by red spheres. The hydrophobic pocket is represented by blue spheres and the position of amino-acid substitution
that were previously shown to result in loss of sensitivity to or dependence on isoflavenes are indicated by the yellow and green spheres,
respectively. (A) A line model of a single capsomere containing one copy of VP1 (light blue), VP2 (pale green), VP3 (light orange) and VP4 (light
magenta). (B) A stick model representing three capsomeres at the three-fold axis of symmetry. (C) A stick model representing five capsomeres at the
five-fold axis of symmetry. (D) An enlargement of the central portion of figure (D) showing the relation between the five-fold axis and the
hydrophobic pockets (E) A further enlargement showing the position of Ser6 of VP3 at the center of the five-fold axis. All views are from an external
viewpoint. An animated ‘‘Interactive 3D Complement’’ (I3DC) for the structures in this figure appears in Proteopedia at http://proteopedia.org/w/
Journal:PLoS_ONE:1.
doi:10.1371/journal.pone.0018360.g004
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outbreaks of poliomyelitis by person-to-person transmission of
minimally diverged OPV and VDPV as is currently occurring in
Nigeria [12,35]. The third problem, continuous or intermittent
excretion by anonymous [36] or immune deficient individuals
[12,37] persistently infected after exposure to polio vaccine (or
wild poliovirus) is more complex and has two facets that must be
dealt with.
The first is to determine the number of epidemiological foci of
persistent infections and identify the responsible individuals
[12,36,38]. To date, less than 40 individuals throughout the world
have been identified as individuals who excrete iVDPVs as a
consequence of persistent poliovirus infections. These individuals
had complete or almost complete B-cell immune deficiencies.
Some individuals were identified after they developed symptoms of
poliovirus infection. Of the remaining individuals who were
identified by chance, some remained asymptomatic while others
eventually developed symptoms of poliovirus infection. Currently,
the number of known individuals with persistent infections has
fallen since persistent infection in some individuals cleared
spontaneously while others are no longer alive. However, the
total number of persistently infected individuals throughout the
world is unknown. Surveys of individuals with B-cell immune
deficiencies for persistent poliovirus infection have so far failed to
identify additional persistently infected individuals [16]. On the
other hand additional persistently infected individuals must exist
since increasing numbers of aVDPVs have been isolated from
sewage samples as more national environmental poliovirus
surveillance programs incorporate environmental surveillance
[12]. Epidemiologically related aVDPVs, like the type 2 s in
Israel [12,19,20], the type 3 s in Estonia [12,39], and the types 1,
2, and 3 in Finland [40] that were intermittently isolated over
Figure 5. Unique amino acid substitutions in the capsid proteins of SD-07-03, an aVDPV2 isolate that reverted genotypically but
not phenotypically to neurovirulence, mapped onto the three-dimensional x-ray crystallographic atomic coordinates of type 2
poliovirus (PDB accession number1EAH). The positions of unique substitutions of SD-07-03 (Table S1), determined as in Fig. 4, were mapped
onto the coordinates of type 2 poliovirus (1EAH) using MacPyMol and are represented by red spheres. The hydrophobic pocket is represented by
blue spheres and the position of amino acid 143 of VP1, one of two determinants for neurovirulence in type 2 poliovirus, is represented by orange
spheres. (A) A line model of a single capsomere containing one copy of VP1 (light blue), VP2 (pale green), VP3 (light orange) and VP4 (light magenta).
(B) A stick model representing three capsomeres at the three-fold axis of symmetry. (C) A stick model representing five capsomeres at the five-fold
axis of symmetry. (D) An enlargement of the central portion of figure (D) showing the relation between the five-fold axis and the hydrophobic
pockets (E) An enlargement showing the position of substituted amino acids Serine141 Asparagine144 and Glycine of VP1 (red spheres) relative amino
acid Threonine143 (orange spheres) of VP1. All views are from an external viewpoint. An animated ‘‘Interactive 3D Complement’’ (I3DC) for the
structures in this figure appears in Proteopedia at http://proteopedia.org/w/Journal:PLoS_ONE:1.
doi:10.1371/journal.pone.0018360.g005
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Unfortunately many countries do not conduct environmental
surveillance, and in those that do, the probability of identifying
anonymous persistent excretors is very low. Thus the global
burden of such strains is unknown.
The second facet of persistent infections is to cure the subjects
affected in order to prevent pre-eradication emergence or post-
eradication re-emergence of foci of poliomyelitis due to person-to-
person transmission of these polioviruses. It may be very difficult to
identify the persistent excretor who triggers a post-eradication re-
emergence after cessation of OPV immunization. However,
responding with reintroduction of vaccination with live polio
vaccine strains by itself might lead to further outbreaks [35,41].
Effective antivirals may offer an alternative community response
[42]. Efforts to cure one immunodeficient individual with
currently available drugs were not effective [23]. To date there
are no approved antiviral drugs for treating poliovirus infections
although gammaglobulin replacement therapy combined with
pleconaril was reported to have eliminated persistence in another
individual [24]. Potential anti-viral drug targets include the 3 C
protease, proteins essential for viral replication, and the capsid
proteins [43]. Isoflavenes are among the group of capsid inhibitors
that intercalate into the hydrophobic pocket of type 2 poliovirus
capsid blocking uncoating and release of viral RNA from capsid
into the cell [4,5]. Mutations conferring resistance or dependence
were either already present or arose rapidly during in vitro
replication of polio type 2 vaccine in the presence of drugs [4].
The majority of the isolates were sensitive to isoflavenes. Isolates
that developed resistance or dependence were only a minor
component of the quasispecies pool and were identified after
plaque selection.
More than one lineage of poliovirus may co-exist in persistently
infected individuals and each lineage is present as a quasispecies.
Multiple lineages were described in at least one persistently
infected, immunodeficient patient [22,28] and inferred [21] from
molecular analyses of aVDPVs recovered from the two uniden-
tified, persistently infected individuals in Israel. In this report, we
demonstrated that the majority of the viruses in the quasispecies
obtained after amplification of at least nine of ten highly diverged
type 2 neurovirulent aVDPV2 plaque isolates recovered from
sewage from these two anonymous sources were still as sensitive in
vitro as Sabin 2 vaccine strains to the in vitro antiviral effects of C-2
and C-10 compounds at concentrations of 20 mM. The remaining
isolate, SD-06-10, was unaffected by the antiviral compounds. It
did not have any unique amino acid substitutions in the
hydrophobic pocket that might have blocked the binding of C2
or C10. Instead, unique amino acid substitutions were observed
far from the drug-binding pocket near the three-fold and at the
five-fold axes of symmetry between capsomeres. Substitution of
amino acids at these sites might alter capsid stability (or pocket
hindrance) and block the access and binding of the C2 or C10
compounds even though they are located at sites remote from the
hydrophobic pocket as observed by Salvati et al. [4].
All ten of the aVDPV2s were genotypically reverted to
neurovirulence [34], i.e., all had reverted at nucleotide position
481 in the 59U T R( At oG )a n da m i n oa c i dr e s i d u e1 4 3o fV P 1
(isoleucine encoded by ATT to threonine encoded by ACT).
Phenotypic reversion for nine of the ten aVDPV2sw a s
determined using the murine transgenic (PVR TG21) neuro-
virulence test. Two different routes of inoculation, i.p. and i.n.
were used and the PVR TG21 mice were observed daily for
clinical signs of paresis and paralysis, or death. Seven of the
genotypically reverted strains were also phenotypically neuro-
virulent by both routes of inoculation. Strain, SD-06-10, which
was resistant to the C2 and C10 antiviral compounds, was
neurovirulent when introduced i.p. but only partially neurovir-
ulent when introduced i.n. Unexpectedly, strain, SD-07-03,
which was sensitive to both antiviral compounds, was only
weakly neurovirulent when administered either by the i.n. or i.p.
route. These results suggest that nucleotide changes in addition
to the two ‘‘classic’’ reversions can modulate the neurovirulence
of poliovirus strains. The VP1 of SD-07-03 had diverged from
Sabin 2 (AY194220) by 14.4%. Four nucleotide substitutions
resulted in three amino acid substitutions in VP1 at residues
141, 144 and 145. These changes (Fig. 5E), Asn141,A s p 144 and
Ala145 to Ser141,A s n 144 and Gly145, respectively, presumably
modulated the phenotypic reversion of a genome with the
‘‘classic’’ neurovirulent genotype for type 2 poliovirus. However,
additional substitutions in capsid proteins and or in the non-
structural proteins or non-coding regions may also have
contributed to the phenotype. The accumulation of substitutions
in these highly diverged aVDPVs is due to natural genetic drift
and digestive tract selective pressure. Relationship between this
genetic drift and neurovirulence is indirect. This can lead to
variants that are more or less neurovirulent in mice. In the case
of the isolates described in this report, all had lost the fully
attenuated phenotype of the Sabin 2 strain.
In conclusion, both isoflavenes worked equally well against
Sabin 2 and most of the highly-diverged aVDPV2s isolated in
Israel. Thus, functionality of the hydrophobic pocket may be
unaffected by mutations that accumulate during selective pressures
exerted during persistent poliovirus infections. The isoflavenes
reduced the poliovirus loads in vitro. These compounds are not
toxic when administered in vivo to mice following different routes of
inoculation and at very high concentration (400 mg/kg) (L.Fiore,
unpublished data). Experiments to evaluate the toxicity of the
compounds on transgenic PVR Tg-21 mice and experiments to
test whether isoflavenes inhibit replication in vivo in these mice are
currently underway as first step to determine whether it may be
possible to use these compounds in humans. Finally, it is worth
mentioning that amino acid substitutions at sites remote from the
drug-binding pocket, and others related to known neurovirulence
attenuation sites may influence the antiviral activity of isoflavenes
and the neurovirulence of the strains.
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